Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 104, Issue 2, Pages 297-300Publisher
WILEY
DOI: 10.1002/cpt.1118
Keywords
-
Categories
Ask authors/readers for more resources
Inhibitors of cholesteryl ester transfer protein (CETP) were developed due to their ability to raise HDL-C levels. Preclinical studies demonstrated favorable effects on atherosclerotic plaque with CETP inhibitory approaches in animal models. While these agents raise HDL-C and lower LDL-C, most have not proven to reduce cardiovascular event rates in large outcome trials. The state of opinion after all of these clinical trials is reviewed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available